What is Arecor?
Arecor is a biopharmaceutical firm dedicated to advancing drug development and delivery solutions, particularly for diabetes and cardiometabolic diseases. The company leverages its proprietary Arestat technology platform to engineer enhanced therapeutic medicines. Through strategic collaborations with leading pharmaceutical and medtech entities, Arecor aims to accelerate the clinical advancement of its innovative treatments. Its operations are further fortified by a strong intellectual property portfolio, validating the efficacy and potential of its technology.
How much funding has Arecor raised?
Arecor has raised a total of $8M across 2 funding rounds:
Private Equity
$230K
Unspecified
$7.8M
Private Equity (2015): $230K with participation from Hygea VCT Plc
Unspecified (2018): $7.8M led by Downing, Albion Capital Group, and Calculus Capital
Key Investors in Arecor
Hygea VCT Plc
Seneca Growth Capital VCT Plc, formerly Hygea vct plc, is a venture capital firm that invests in growing UK businesses, providing access to a diversified range of growth capital investments.
Albion Capital Group
AlbionVC, the technology investment arm of Albion Capital Group LLP, specializes in high-growth B2B software and technology-enabled services, primarily investing from seed to Series B in UK-based companies.
Calculus Capital
Calculus Capital is an investment manager focused on tax-efficient growth capital for UK smaller companies, investing in technology, healthcare, and creative industries through VCTs and EIS funds.
What's next for Arecor?
The recent major strategic investment positions Arecor for accelerated growth and the scaling of its innovative drug delivery technologies. This capital is expected to fuel further clinical development, expand its pipeline, and potentially broaden its strategic partnerships. The company's focus on diabetes and cardiometabolic diseases, coupled with its proprietary Arestat platform, suggests a strategic push towards addressing significant unmet medical needs in these therapeutic areas. Future endeavors will likely involve advancing existing candidates through clinical trials and exploring new applications for its technology.
See full Arecor company page
